FDMT stock touches 52-week low at $4.42 amid sharp annual decline

In a challenging year for 4D Molecular Therapeutics (FDMT), the biotech company’s stock has hit a 52-week low, trading at $4.42. According to InvestingPro data, while the company maintains a strong current ratio of 17.33 and holds more cash than debt, it’s quickly burning through its resources. This price point marks a significant downturn for the company, which has seen its stock value plummet by -83.11% over the past year. Investors have been wary as the company navigates through a tough period marked by broader market volatility and sector-specific headwinds. The steep decline in FDMT’s stock price reflects investor sentiment and the hurdles the company faces in its path to recovery and growth. Analyst price targets range from $6 to $72, suggesting significant uncertainty about the company’s prospects. For deeper insights into FDMT’s financial health and growth potential, access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers this and 1,400+ other US stocks.

In other recent news, 4D Molecular Therapeutics has been the subject of several assessments by financial analysts in light of recent developments. Jefferies reduced the company’s target to $40, citing the latest durability data in Phase 2 for patients with broad/newly diagnosed wet Age-related Macular Degeneration (wAMD). Despite a decrease in patients remaining injection-free, the treatment burden reduction of 83% and 94% is viewed as positive. 4D Molecular Therapeutics is planning two Phase 3 trials for wAMD, with a market launch for the treatment anticipated in 2029.

H.C. Wainwright reaffirmed a Buy rating on 4D Molecular Therapeutics, noting the positive results from the Phase 2b PRISM trial for 4D-150, a gene therapy candidate for wet AMD (NASDAQ:AMD). Leerink Partners adjusted its target for 4D Molecular Therapeutics to $27, following updates to its pipeline, including the prioritization of the 4D-150 program. However, BMO Capital Markets downgraded 4D Molecular Therapeutics to Market Perform, citing concerns over the potential market reach and durability of 4D-150.

These updates are part of the recent developments for 4D Molecular Therapeutics. As the company continues its research and development efforts, investors and analysts are keenly observing the progress of its clinical trials and the potential impact on its market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.